Abstract: A method for computer question answering includes, at a retriever subsystem of a question answering computer system, identifying a plurality of relevant text evidence strings for an input text question. At a linker subsystem of the question answering computer system, one or more of the plurality of relevant text evidence strings are associated with a respective secondary text evidence string to form a plurality of evidence chains via a previously-trained entity-linking machine-learning model. At a chainer subsystem of the question answering computer system, a ranked set of the evidence chains is identified based at least in part on an output of a generative machine-learning model applied to each of the plurality of evidence chains. At a reader subsystem of the question answering computer system, an answer to the input text question is output based at least in part on the ranked set of evidence chains.

Abstract: A computing system includes a logic subsystem and a storage subsystem holding instructions executable by the logic subsystem to implement a transformer-based text encoder. The transformer-based text encoder includes a plurality of transformer blocks previously-trained to apply encoding operations to computer-readable text representations of input text strings, the computer-readable text representations including computer-readable question representations of input text questions, and computer-readable passage representations of input text passages. The plurality of transformer blocks include a shared transformer block trained for both the computer-readable question representations and the computer-readable passage representations and a specialized transformer block including two or more input-specific subnetworks, and a routing function to select an input-specific subnetwork of the two or more input-specific subnetworks for each of the computer-readable text representations.

Abstract: The present disclosure provides an apparatus and a method for hydrate-based wastewater treatment and cold storage. The apparatus for hydrate-based wastewater treatment and cold storage includes a water chilling unit, a hydrate-based cold storage tank, an airflow disturbance device, a water layer positioning system, a spraying system, a suction filtration system, a heat exchange system, and a system monitoring device. The water chilling unit provides a secondary refrigerant at a low temperature. The secondary refrigerant flows through an evaporator coil in the hydrate-based cold storage tank for heat exchange. The airflow disturbance device induces hydrate nucleation. The water layer positioning system positions a contact surface between a water layer and a hydrate former after hydrate decomposition to facilitate drawing and separation of the treated upper water layer. The spraying system and the suction filtration system enhance the solid-liquid separation efficiency to improve the removal rate of pollutants.

Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.

Abstract: This disclosure relates to anti-CD3e (T-cell surface glycoprotein CD3 epsilon chain) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.

Abstract: Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.

Abstract: Embodiments of the invention are directed to compounds that inhibit an activity of EP AC proteins and methods of using the same. The inventors have developed a sensitive and robust high throughput screening (HTS) assay for the purpose of identifying EPAC specific inhibitors (Tsalkova et al. (2012) PLOS ONE 7(1):e30441).

Abstract: This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.